Zydus Gets CDSCO Panel Nod for Phase III Trial of Dextromethorphan, Phenylephrine Cough Syrup FDC

Published On 2025-10-06 14:29 GMT | Update On 2025-10-06 14:29 GMT

New Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has granted permission to Zydus Healthcare Limited to conduct a Phase III clinical trial for its fixed-dose combination syrup containing Dextromethorphan Hydrobromide IP 10 mg and Phenylephrine Hydrochloride IP 5 mg per 5 ml.

The decision follows the Committee’s earlier recommendation dated July 9, 2025, after which Zydus Healthcare presented their proposal along with revised Phase III clinical trial protocol before the committee.

Dextromethorphan is an NMDA receptor antagonist used to treat cases of dry cough.It is a low-affinity uncompetitive NMDA antagonist and sigma-1 receptor agonist. It is also an antagonist of α3/β4 nicotinic receptors. However, the mechanism by which dextromethorphan's receptor agonism and antagonism translate to a clinical effect is not well understood.

Also Read: Zydus Secures CDSCO Panel Go-Ahead For Phase III Trial of Empagliflozin-Metoprolol FDC

Phenylephrine is an alpha-1 adrenergic agonist used in the management of hypotension, generally in the surgical setting associated with the use of anesthetics.

At the recent SEC meeting for pulmonary drugs, the expert panel reviewed Zydus Healthcare's proposal along with the revised Phase III clinical trial protocol.

After detailed deliberation, the committee recommended for the grant of permission to conduct the Phase III clinical trial. Accordingly, the expert panel suggested that the firm should submit the Phase III CT report to CDSCO for further review by the committee.

Also Read: Zydus Lifesciences gets NOC from Health Canada for hypothyroidism tablets

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Susmita Roy

Susmita Roy, B pharm, M pharm Pharmacology, graduated from Gurunanak Institute of Pharmaceutical Science and Technology with a bachelor's degree in Pharmacy. She is currently working as an assistant professor at Haldia Institute of Pharmacy in West Bengal. She has been part of Medical Dialogues since March 2021.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Zydus Gets CDSCO Panel Nod for Phase III Trial of Dextromethorphan, Phenylephrine Cough Syrup FDC

Similar News

Zydus Lifesciences Secures CDSCO Panel Approval for Usnoflast Capsule Interaction Study

CDSCO Flags MSD Pharma's Cancer Drug Trial Over Indian Representation, Control Arm

MSD Pharma gets CDSCO panel nod for New Indications of Pembrolizumab in India

CDSCO Panel Directs Malik Lifesciences to Revise Phase III Trial Protocol for Tamsulosin, Dutasteride, Tadalafil FDC

MSN Lab gets CDSCO panel nod for Phase IV CT of Tofacitinib Tablets 10 mg

SEC Recommends Phase III Trial of MSN Labs' Vibegron Against Mirabegron in Overactive Bladder

Not All Combipacks Are New Drugs: CDSCO Defines Approval Rules for Lyophilized Injections